# NeoMega36®

**Supporting the development of normal vision function in extremely preterm infants**

### Why supplement with NeoMega36®?

- ARA and DHA are essential for brain and retinal development. In utero accretion of these fatty acids peaks during the third trimester, a critical period that extremely preterm infants miss.
- Compensates insufficient endogenous synthesis and low postnatal DHA/ARA blood levels in infants born before about 28–29 weeks' gestation.
- Supports postnatal growth and body composition; higher arachidonic acid status is associated with better growth during the first year of life.
- Combined, adequately dosed DHA/ARA supplementation of extremely preterm infants is linked with favourable brain white matter growth until term, and improved ophthalmologic outcomes, including reduced risk or severe ROP.

### Product Profile

#### Indication

Supports the development of normal vision function in extremely preterm infants.

#### Target Population

Extremely preterm infants, <28 weeks
or birth weight <1000 g.

#### Ingredients:

**ARA**-rich oil from the fungi Mortierella alpina, **DHA**-rich oil from the microalgae Schizochytrium, sunflower oil, antioxidants.

#### Storage

Keep in refrigerator (2-8 °C).
Opened bottle can be used for 7 days.

#### Administration

Easy Administration orally by conneting an oral syringe, or through a nasogastric tube.

Important notices: must only be used under medical supervision, not for use as a sole source of nutrition, and for enteral use only.

#### Daily Dosage:

0.4 ml/kg once daily, corresponding to 100 and 50 mg/kg/day of ARA and DHA.

#### Duration

Start as soon as possible after birth, e.g. first or second day of life. Continue until discharge or until post-conceptional week 40.

#### Delivery Unit

Unit of 6 x 5 ml bottles
Article number: 17350153820025

#### How to order:

orders@neobiomics.eu


**NeoMega36® is classified as a Food for Special Medical Purposes (FSMP) in the EU**

www.neomega36.eu

MADE IN EU